Arora S - Search Results

1

Highly potent triazole-based tubulin polymerization inhibitors.

Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Zhang Q, et al. Among authors: arora s. J Med Chem. 2007 Feb 22;50(4):749-54. doi: 10.1021/jm061142s. Epub 2007 Jan 24. J Med Chem. 2007. PMID: 17249649 Free PMC article.

2

Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.

Arora S, Wang XI, Keenan SM, Andaya C, Zhang Q, Peng Y, Welsh WJ. Arora S, et al. Cancer Res. 2009 Mar 1;69(5):1910-5. doi: 10.1158/0008-5472.CAN-08-0877. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223556 Free PMC article.

3

Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.

Peng Y, Zhang Q, Arora S, Keenan SM, Kortagere S, Wannemacher KM, Howells RD, Welsh WJ. Peng Y, et al. Among authors: arora s. Bioorg Med Chem. 2009 Sep 1;17(17):6442-50. doi: 10.1016/j.bmc.2009.07.007. Epub 2009 Jul 9. Bioorg Med Chem. 2009. PMID: 19646882

4

Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and study of their effect on the cell cycle.

Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Garaliene V, Welsh W, Arora S, Farruggia G, Masotti L. Andreani A, et al. Among authors: arora s. J Med Chem. 2005 Aug 25;48(17):5604-7. doi: 10.1021/jm050353e. J Med Chem. 2005. PMID: 16107161

5

Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach.

Wang CY, Ai N, Arora S, Erenrich E, Nagarajan K, Zauhar R, Young D, Welsh WJ. Wang CY, et al. Among authors: arora s. Chem Res Toxicol. 2006 Dec;19(12):1595-601. doi: 10.1021/tx060218k. Chem Res Toxicol. 2006. PMID: 17173372 Free PMC article.

6

Application of screening methods, shape signatures and engineered biosensors in early drug discovery process.

Hartman I, Gillies AR, Arora S, Andaya C, Royapet N, Welsh WJ, Wood DW, Zauhar RJ. Hartman I, et al. Among authors: arora s. Pharm Res. 2009 Oct;26(10):2247-58. doi: 10.1007/s11095-009-9941-z. Epub 2009 Jul 22. Pharm Res. 2009. PMID: 19626425

7

Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.

Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, Ortiz PA, Hait WN. Arora S, et al. Cancer Res. 2003 Oct 15;63(20):6894-9. Cancer Res. 2003. PMID: 14583488

8

P-glycoprotein mediates resistance to histidine kinase inhibitors.

Arora S, Yang JM, Utsumi R, Okamoto T, Kitayama T, Hait WN. Arora S, et al. Mol Pharmacol. 2004 Sep;66(3):460-7. doi: 10.1124/mol.66.3.. Mol Pharmacol. 2004. PMID: 15322237

9

Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase.

Arora S, Yang JM, Hait WN. Arora S, et al. Cancer Res. 2005 May 1;65(9):3806-10. doi: 10.1158/0008-5472.CAN-04-4036. Cancer Res. 2005. PMID: 15867377

10

Detection of anti-elongation factor 2 kinase (calmodulin-dependent protein kinase III) antibodies in patients with systemic lupus erythematosus.

Arora S, Yang JM, Craft J, Hait W. Arora S, et al. Biochem Biophys Res Commun. 2002 May 10;293(3):1073-6. doi: 10.1016/S0006-291X(02)00324-8. Biochem Biophys Res Commun. 2002. PMID: 12051769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,932 results

Search Page

Filters